Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Magle Chemoswed Holding AB's average EBITDA Per Share Growth Rate was -139.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Magle Chemoswed Holding AB was 48.60% per year. The lowest was 14.30% per year. And the median was 29.30% per year.
Magle Chemoswed Holding AB (OSTO:MAGLE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Magle Chemoswed Holding AB 3-Year EBITDA Growth Rate Related Terms
OSTO:MAGLE vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Magle Chemoswed Holding AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Magle Chemoswed Holding AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Magle Chemoswed Holding AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Magle Chemoswed Holding AB's 3-Year EBITDA Growth Rate falls into.
Magle Chemoswed Holding AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Magle Chemoswed Holding AB (OSTO:MAGLE) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Magle Chemoswed Holding AB and its competitors. Over the past decade, Magle Chemoswed Holding AB's 3-Year EBITDA Growth Rate has ranged from 14.30 to 48.60. According to the industry distribution chart, Magle Chemoswed Holding AB ranks #999999 out of 1127 companies in the Biotechnology industry.
Is Magle Chemoswed Holding AB's 3-Year EBITDA Growth Rate too high?
Magle Chemoswed Holding AB's current 3-Year EBITDA Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 14.30 to a high of 48.60. Based on the distribution chart, Magle Chemoswed Holding AB ranks #999999 out of 1127 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Magle Chemoswed Holding AB has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Magle Chemoswed Holding AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Magle Chemoswed Holding AB ranks #999999 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Magle Chemoswed Holding AB in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Historically, Magle Chemoswed Holding AB's own 3-Year EBITDA Growth Rate has ranged from 14.30 to 48.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Magle Chemoswed Holding AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Magle Chemoswed Holding AB's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Magle Chemoswed Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Magle Chemoswed Holding AB (OSTO:MAGLE) is currently considered Possible Value Trap. The stock's GF Value™ is kr23.43, compared to a current price of kr0.31 — trading 98.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Magle Chemoswed Holding AB's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Magle Chemoswed Holding AB (OSTO:MAGLE), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Magle Chemoswed Holding AB (OSTO:MAGLE) Overvalued in 2026?
Based on GuruFocus' analysis, Magle Chemoswed Holding AB stock appears to be undervalued.
The current stock price of kr0.31 is trading 98.7% below its estimated GF Value™ of kr23.43.
GuruFocus considers Magle Chemoswed Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:MAGLE:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: kr23.43 vs. price of kr0.31 (98.7% below fair value)
No single metric tells the full story. See the OSTO:MAGLE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
39GF Score
Get the complete analysis for OSTO:MAGLE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MAGLE has been successfully added to your 
